We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Ultra-Sensitive ctDNA Assay Significantly Improves Detection Rates for Early-Stage Lung Cancer

By LabMedica International staff writers
Posted on 27 Oct 2023
Print article
Image: The Personalis NeXT Personal cancer assay is designed to detect and monitor residual and recurrent disease (Photo courtesy of 123RF)
Image: The Personalis NeXT Personal cancer assay is designed to detect and monitor residual and recurrent disease (Photo courtesy of 123RF)

The existing method for confirming a recurrence of non-small cell lung cancer (NSCLC), the most frequent form of lung cancer, largely relies on imaging techniques like CT scans, which have known limitations in terms of sensitivity. Now, initial findings from a groundbreaking lung cancer study mark a significant advancement in lung cancer circulating tumor DNA (ctDNA) detection and management.

Personalis, Inc. (Menlo Park, CA, USA) has developed the NeXT Personal cancer assay for identifying and monitoring minimal residual and recurrent disease (MRD). The assay has demonstrated considerably higher detection rates for early-stage lung cancer, including lung adenocarcinoma (LUAD), a subtype of NSCLC that is notably challenging to identify in blood tests. The NeXT Personal technology employs whole genome sequencing and advanced noise suppression technology called NeXT SENSE to isolate a distinct genetic signature from a patient's tumor. This signature, based on around 1,800 variants, is then monitored over time in the patient's blood to identify any recurring or residual cancer. The technology boasts an industry-leading sensitivity level that goes down to about 1 PPM, which opens up the possibility for earlier risk assessment, early detection, more accurate monitoring, and thus, a significant improvement in lung cancer management.

For the current analysis, NeXT Personal was used to identify and track MRD in over 170 patients who were part of the TRACERx lung cancer study group. The assay displayed significantly higher sensitivity in detecting early-stage NSCLC compared to findings reported in two earlier studies focused on the TRACERx cohort. Before surgical intervention, NeXT Personal demonstrated a 100% sensitivity rate for ctDNA in non-LUAD samples and an 81% sensitivity rate for LUAD. This represents up to a fourfold increase in pre-surgical sensitivity for early-stage LUAD compared to prior research, significantly enhancing the assay's ability to effectively monitor lung cancer.

The study also revealed that NeXT Personal could classify patients into groups with lower or higher risks of cancer recurrence based on pre-surgical ctDNA levels. This ultra-sensitive ctDNA detection capability was pivotal in assessing patient recurrence risk. For instance, patients with LUAD who had no detectable ctDNA before surgery showed an impressive 100% overall five-year survival rate and a 94% relapse-free survival rate. In contrast, those with detectable ctDNA faced a high risk of cancer recurrence over a five-year period.

Moreover, NeXT Personal allowed for earlier detection of residual or recurring lung cancer post-surgery. The data indicate a median lead time of around 6 to 11 months for ctDNA detection ahead of conventional imaging methods, and substantially longer than previous findings from the TRACERx study. This earlier detection can potentially facilitate quicker treatment interventions for patients at higher risk. Overall, the findings from the TRACERx study underscore the potential utility of NeXT Personal in guiding patient management from the pre-surgery phase through to post-operative care and long-term monitoring.

"Existing tests for lung cancer patients often fall short in detecting residual or recurrent cancer early,” said Richard Chen, MD, MS, Chief Medical Officer and Executive Vice President, R&D of Personalis. “Our NeXT Personal test is designed to change that by being significantly more sensitive. We are thrilled that the TRACERx results presented at ESMO demonstrated higher sensitivity for the most common types of early-stage lung cancer, including the most challenging subtypes. That sensitivity translated into a better understanding of recurrence risk for patients, and earlier detection of recurrence. We hope that earlier detection can ultimately be life-saving, offering patients a greater chance at successful treatment."

Related Links:
Personalis, Inc.

Platinum Supplier
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Gold Supplier
Blood Glucose Reference Analyzer
Nova Primary
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Silver Supplier
Immunoblots for Myositis Diagnostics
EUROLINE Myositis Profiles

Print article

Channels

Clinical Chemistry

view channel
Image: A module with eight micro-devices, complete with microfluidic channels and drive motors (Photo courtesy of U.S Department of Energy)

Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses

Understanding the acidity or alkalinity of substances through pH measurement is crucial in many fields, from environmental monitoring to healthcare product safety. In many cases, these measurements must... Read more

Hematology

view channel
Image: The QScout hematology analyzer has received US FDA 510(k) clearance (Photo courtesy of Ad Astra Diagnostics)

First Rapid-Result Hematology Analyzer Reports Measures of Infection and Severity at POC

Sepsis, a critical medical condition that arises as an extreme response to infection, poses a significant health threat. It occurs when an infection triggers a widespread inflammatory response in the body.... Read more

Immunology

view channel
Image: PointCheck is the world’s first device for non-invasive white cell monitoring (Photo courtesy of Leuko Labs)

World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw

One of the toughest challenges for cancer patients undergoing chemotherapy is experiencing a low count of white blood cells, also known as neutropenia. These cells play a crucial role in warding off infections.... Read more

Microbiology

view channel
Image: Current testing methods for antibiotic susceptibility rely on growing bacterial colonies in the presence of antibiotics (Photo courtesy of 123RF)

Rapid Antimicrobial Susceptibility Test Returns Results within 30 Minutes

In 2019, antimicrobial resistance (AMR) was responsible for the deaths of approximately 1.3 million individuals. The conventional approach for testing antimicrobial susceptibility involves cultivating... Read more

Pathology

view channel
Image: AI methods used in satellite imaging can help researchers analyze tumor images (Photo courtesy of Karolinska Institutet)

AI Approach Combines Satellite Imaging and Ecology Techniques for Analysis of Tumor Tissue

Advancements in tumor imaging technology have significantly enhanced our ability to observe the minute details of tumors, but this also brings the challenge of interpreting vast amounts of data generated... Read more

Industry

view channel
Image: The acquisition significantly expands Medix Biochemica’s portfolio of IVD raw materials (Photo courtesy of ViroStat)

Medix Biochemica Acquires US-Based ViroStat to Expand Infectious Diseases Antibody Offering

Medix Biochemica (Espoo, Finland), a supplier of critical raw materials to the in vitro diagnostics (IVD) industry, has acquired ViroStat LLC (Portland, ME, USA), a provider of infectious disease antibodies... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.